Literature DB >> 19828765

Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Wendell D Zollinger1, Elizabeth E Moran, Deborah H Schmiel.   

Abstract

Serum bactericidal antibodies are important for protection against systemic Neisseria meningitidis infections. Consequently, identifying the specific targets of bactericidal antibodies is important for understanding protective immunity to meningococcal disease and for vaccine development and evaluation. We have developed a new assay that can be used to investigate the specificity of serum bactericidal antibodies. Prior to testing for bactericidal activity, antibodies specific for a given antigen or group of antigens are depleted from a serum sample by incubation with the antigen(s) bound to the wells of a 96-well microplate. A dilution series of the antigen is bound to the plate to assess the effectiveness of the antigen in removing the bactericidal antibodies. Removal of antibodies with solid-phase antigen prior to bactericidal testing avoids depletion of complement by soluble immune complexes that can form when soluble antigen is present in the bactericidal test mixture (direct inhibition). The parameters associated with this assay are investigated and compared with those associated with a direct-inhibition assay. The bactericidal depletion assay can be an effective tool for studying the specificity of serum bactericidal antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828765      PMCID: PMC2786375          DOI: 10.1128/CVI.00255-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.

Authors:  Makda Fisseha; Ping Chen; Brenda Brandt; Todd Kijek; Elizabeth Moran; Wendell Zollinger
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

Review 3.  Development of vaccines against meningococcal disease.

Authors:  Luis Jódar; Ian M Feavers; David Salisbury; Dan M Granoff
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

4.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Authors:  M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

Review 5.  Towards an improved serogroup B Neisseria meningitidis vaccine.

Authors:  Kirsten P Perrett; Andrew J Pollard
Journal:  Expert Opin Biol Ther       Date:  2005-12       Impact factor: 4.388

6.  Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Berhanu Melak; Degu Berhanu; Morten Harboe; Jan Kolberg; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

7.  Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.

Authors:  Jamie Findlow; Ann Holland; Nick Andrews; Vincent Weynants; Franklin Sotolongo; Paul Balmer; Jan Poolman; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

8.  Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

Authors:  Vincent E Weynants; Christiane M Feron; Karine K Goraj; Martine P Bos; Philippe A Denoël; Vincent G Verlant; Jan Tommassen; Ian R A Peak; Ralph C Judd; Michael P Jennings; Jan T Poolman
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

9.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.

Authors:  Maria Jose Uria; Qian Zhang; Yanwen Li; Angel Chan; Rachel M Exley; Bridget Gollan; Hannah Chan; Ian Feavers; Andy Yarwood; Raquel Abad; Ray Borrow; Roland A Fleck; Barbara Mulloy; Julio A Vazquez; Christoph M Tang
Journal:  J Exp Med       Date:  2008-05-26       Impact factor: 14.307

View more
  3 in total

1.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

2.  Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.

Authors:  Elizabeth E Moran; Robert Burden; Joseph E Labrie; Zhiyun Wen; Xin-Min Wang; Wendell D Zollinger; Lan Zhang; Valerian B Pinto
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

3.  The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.

Authors:  Valerian B Pinto; Robert Burden; Allyn Wagner; Elizabeth E Moran; Che-Hung Lee
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.